ALung Technologies raises $10.8 million
Artificial lung-like device developer ALung Technologies raised $10.8 million in a new round of debt financing according to an SEC filing posted this week. The money already raised in the round comes from 63 unnamed investors, according to the SEC filing. Pittsburgh-based ALung’s Hemolung device is an extracorporeal carbon dioxide removal system that works by removing carbon dioxide and delivering oxygen directly to a patient’s blood via a small catheter inserted into the jugular or femoral vein. The company said that the remaining $1.2 million it looks to raise includes notes that are to be issued to Equinox Securities Melvin Pirchesky as part of a commission, according to the filing. Early last month, ALung Technologies said its Hemolung RAS extracorporeal carbon dioxide removal device was selected for use in the world’s 1st pivotal trial of ECCO2R technology used to treat patients with acute respiratory failure. The U.K.’s National Institute for Health Research will supply $3.1 million (GBP £2.1 million) in funding for the 1,120 patient Rest trial, which looks to examine the effect of protective ventilation with veno-venous lung assist devices during respiratory failure. The trial will be jointly led by Queen’s University and Belfast Health and Social Services Trust, the company said. The post ALung Technologies raises $10.8 million appeared first on MassDevice.
Ruud H. Knols, Nicolas Fischer, Dario Kohlbrenner, Anastasios Manettas, Eling D. de Bruin
The U.S. Food and Drug Administration (FDA) has cleared artificial intelligence...Read more on AuntMinnie.comRelated Reading: Mirada upgrades radiation treatment software Mirada introduces AI software for radiation oncology Optellum, Mirada present lung cancer study at RSNA 2017 Mirada's deep-learning contours match human-drawn contours Mirada showcases XD:PACS at RSNA 2016
A 39-year-old non-smoker woman was admitted in the thoracic oncology unit of the Montpellier Academic Hospital in June 2017 for investigation of multiple lung consolidations, fever, and respiratory failure. She was followed-up since infancy for a cystic fibrosis with cystic fibrosis transmembrane conductance regulator (CFTR) mutation ( ΔF508-CFTR). Two years ago, a lung allograft was decided, owing to rapid onset of respiratory function impairment, and she received a bi-pulmonary transplant. According to the donor database, the lung transplant was removed from a 57-year-old woman with a 30 pack-year smoking history.
In this study, we investigated the role of RN in IR-induced lung injury. To study IR-induced cell-death, we simulated LTx procedure using our cell culture model with human lung epithelial (BEAS-2B) cells. After 18 h of cold ischemic time (CIT) followed by reperfusion, caspase-independent cell-death, mitochondrial-ROS production and mitochondrial-membrane permeability were significantly increased. ALLN (calpain inhibitor) or necrostatin-1 (Nec-1; RIPK1 inhibitor) reduced these changes. ALLN altered RIPK1/RIPK3 expression and MLKL phosphorylation, whereas Nec-1 did not change calpain/calpastatin expression. Furthermore, STAT...
Clinical Transplantation,Volume 0, Issue ja, -Not available-.
We present here the incidence and long-term outcome of BOS occurring after HSCT in an extended cohort of 110 patients monitored with home spirometry.
Publication date: Available online 8 February 2018Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAuthor(s): Brian M. Will, Scott M. Peters, Sidney B. Eisig, John T. Grbic, Michael A. McKenzie, Angela J. Yoon, Elizabeth M. Philipone
Publication date: Available online 17 July 2018Source: Journal of Hospital InfectionAuthor(s): M. Monteagudo Vela, B. Zych, D. Garcia Saez, A. Simon
AbstractRespiratory-gated18F-fluorodeoxygluocse (18F-FDG) PET/CT has been successfully used to better localize malignancies in the lung or upper abdominal organs. However, clinical usefulness of respiratory-gated18F-FDG PET/CT in detection of fever focus has not been reported yet. A 68-year-old male patient with a history of living donor liver transplantation and biliary stenting was referred for18F-FDG PET/CT due to fever of unknown origin (FUO). To find the accurate fever focus, respiratory-gated and non-gated18F-FDG PET/CT was performed. Respiratory-gated PET/CT readily revealed prominent hypermetabolic lesion in the di...
This study is able to show uniform results that lie on a single side of the hemostatic scale (no thromboses, some bleeding). It is this type of result that can lead us to be conservative with anticoagulation. However, this trial is rare in the evolution of mechanical circulatory support (MCS) device management.